PaxMedica Inc. Common Sto... (PXMD)
0.05
0.01 (25.00%)
At close: Jan 14, 2025, 8:00 PM
undefined% (undefined)
| Bid | n/a |
| Market Cap | 587.48K |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.77 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | n/a |
| Volume | 54,313 |
| Avg. Volume (20D) | 61,260 |
| Open | 0.06 |
| Previous Close | 0.04 |
| Day's Range | 0.04 - 0.06 |
| 52-Week Range | 0.03 - 1.19 |
| Beta | undefined |
About PXMD
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomi...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 2022
Employees 6
Stock Exchange NASDAQ
Ticker Symbol PXMD
Website https://www.paxmedica.com
Analyst Forecast
According to 1 analyst ratings, the average rating for PXMD stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 5455.56% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
9 months ago ·
Source
+21.2%
PaxMedica shares are trading higher after the comp...
Unlock content with
Pro Subscription
9 months ago ·
Source
-10.81%
PaxMedica shares are trading higher after the company received an emergency request form the Ministry of Health of Malawi, asking for emergency access to IV suramin.
